Hypothyroidism: Causes, Symptoms, Diagnosis, and Treatment

What is hypothyroidism, and what is genuinely at stake?

The thyroid sits in the front of the neck and secretes T4 and T3, hormones that act on receptors in nearly every tissue in the body. When output falls, cellular metabolism, heart rate, and protein turnover slow down, producing a recognizable but nonspecific symptom pattern: fatigue, weight gain, cold intolerance, and cognitive slowing among them.

Thyroid hormone production is governed by a feedback loop. The hypothalamus releases thyrotropin-releasing hormone (TRH), which prompts the pituitary to release TSH, which in turn drives the thyroid to make T4 and T3. In primary hypothyroidism, the thyroid gland itself is failing, so TSH rises as the pituitary tries harder to stimulate a gland that cannot respond, while free T4 falls. In the much rarer secondary (pituitary) or tertiary (hypothalamic) forms, TSH may be low or inappropriately normal despite low T4, because the signal itself is deficient rather than the gland.

This distinction is the single most useful fact in interpreting a thyroid panel: a high TSH with a low free T4 points to the gland; a low or normal TSH with a low free T4 points upstream, and usually prompts imaging of the pituitary rather than simply raising the levothyroxine dose. Delayed recognition of secondary hypothyroidism has been described in case reports of pituitary damage occurring years earlier, for example, a 2026 case report describes severe low sodium levels as the presenting sign of pituitary failure (Sheehan syndrome, caused by postpartum pituitary injury) diagnosed roughly two decades after the triggering delivery (case report, 2026). This is a single case report, not population-level evidence, but it illustrates why an unexpectedly low or "inappropriately normal" TSH in a hypothyroid-seeming patient deserves a pituitary workup rather than a reflexive levothyroxine increase.

Hypothyroidism is common, and estimates from U.S. population surveys generally place overall prevalence (overt plus subclinical disease combined) in the mid single digits of the adult population, with women and adults over 60 disproportionately affected. Readers should treat any more precise percentage as an approximation pending verification against the primary survey data, since exact figures vary by survey year and diagnostic threshold used.

What causes hypothyroidism?

Hashimoto's thyroiditis is the dominant cause of primary hypothyroidism in countries, including the United States, where dietary iodine is adequate. It is an autoimmune disease in which antibodies against thyroid peroxidase (anti-TPO) and thyroglobulin gradually damage the gland. Anti-TPO antibodies are detectable in the large majority of confirmed Hashimoto's cases and support the autoimmune diagnosis, though antibody titer itself does not track disease severity or guide dosing. The gland sometimes enlarges early (goiter) and then shrinks over years as follicles are destroyed. Women are affected substantially more often than men, with peak onset typically in mid-adulthood.

Medication-induced hypothyroidism. Amiodarone (used for atrial fibrillation) is iodine-rich and can push the thyroid toward either hypothyroidism or hyperthyroidism depending on the patient's baseline gland status. Checkpoint inhibitor cancer therapies (such as pembrolizumab) are a recognized cause of immune-related thyroid dysfunction, including hypothyroidism, and thyroid function is routinely monitored during treatment. Lithium and interferon-alpha are other recognized drug causes.

Postpartum thyroiditis. A meaningful minority of women develop a transient thyroiditis in the first year after delivery, classically with a brief hyperthyroid phase followed by a hypothyroid phase. Some of these women go on to develop permanent hypothyroidism in the following years, which is why postpartum thyroid symptoms deserve follow-up testing rather than being dismissed as normal postpartum fatigue.

Iodine deficiency remains the leading cause of hypothyroidism worldwide, though it is uncommon in the iodine-fortified food supply of the United States. Paradoxically, very high iodine intake (from kelp supplements, for example) can also suppress thyroid hormone synthesis in susceptible people, a phenomenon known as the Wolff-Chaikoff effect.

What symptoms should prompt thyroid testing?

Symptoms reflect slowed metabolism and tend to accumulate gradually, which is one reason diagnosis is often delayed by many months after onset:

• Fatigue and unexplained weight gain
• Cold intolerance
• Constipation
• Dry skin, brittle nails, hair thinning
• A resting heart rate that runs slower than usual
• Slowed reflexes
• Brain fog, trouble concentrating, low mood
• Elevated LDL cholesterol
• Menstrual irregularity and reduced fertility
• Muscle aches and joint stiffness

These symptoms overlap heavily with perimenopause, depression, and general fatigue, which is a common reason hypothyroidism is missed or misattributed for a period of time before testing.

Untreated, severe hypothyroidism can progress to myxedema coma, a rare but life-threatening emergency involving hypothermia, altered consciousness, slowed breathing, and cardiovascular collapse. This is a medical emergency requiring hospital-level care; anyone with hypothyroidism who develops confusion, extreme lethargy, or difficulty breathing needs urgent evaluation, not a routine follow-up appointment.

Diagnosis: what the labs actually mean

TSH is the standard first-line screening test for thyroid dysfunction in a patient whose pituitary is functioning normally. Because TSH responds to even small changes in thyroid hormone before free T4 moves outside its own reference range, it detects most cases of primary thyroid failure earlier than T4 testing alone.

Clinical guideline bodies, including the American Thyroid Association (ATA) and the Endocrine Society, generally define overt hypothyroidism as a TSH above the upper limit of the lab's reference range together with a low free T4, and subclinical hypothyroidism as an elevated TSH with a free T4 still in the normal range. Because transient TSH elevation can occur during acute illness ("sick euthyroid" patterns) or lab variability, a single abnormal TSH is usually confirmed with a repeat test some weeks later before treatment begins in a nonpregnant adult who is not obviously symptomatic.

Free T4 versus total T4. Free T4 is preferred because, unlike total T4, it is not distorted by changes in binding proteins caused by pregnancy, oral contraceptives, or liver disease.

Anti-TPO antibodies. Testing supports an autoimmune diagnosis and helps predict which patients with subclinical hypothyroidism are more likely to progress to overt disease, though the exact annual progression rate varies across studies and should not be quoted as a fixed number without checking the specific source population.

Reverse T3. Reverse T3 is not part of standard diagnostic panels, is not endorsed by major guideline bodies for routine evaluation, and its clinical utility for detecting thyroid problems in a patient with normal TSH remains disputed.

Subclinical hypothyroidism: the genuinely contested decision

Subclinical hypothyroidism (a mildly elevated TSH, roughly in the range above the lab's upper limit but below about 10 mIU/L, with a normal free T4) is common, particularly in older women, and it is one of the more debated treatment questions in endocrinology.

A large randomized trial in older adults with subclinical hypothyroidism (the TRUST trial, published in the New England Journal of Medicine in 2017) found no meaningful difference in hypothyroid symptoms, fatigue, or quality-of-life scores between levothyroxine and placebo over one year of follow-up. On the strength of this and similar trial evidence, guideline bodies including the ATA and the American College of Physicians generally counsel against routine levothyroxine treatment in adults over 65 with TSH below roughly 10 mIU/L, unless the patient has clear symptoms or elevated cardiovascular risk that specifically argues for treatment.

In adults under 65 with a persistently higher TSH (roughly 7 to 10 mIU/L or above), a time-limited treatment trial is a reasonable, guideline-consistent option, especially with symptoms, positive anti-TPO antibodies, unfavorable cholesterol changes, or pregnancy plans. This is a shared decision between clinician and patient, not a default that follows automatically from a single lab value.

Evidence boundary: it is established that overt hypothyroidism (elevated TSH plus low free T4) should be treated. It is established, from randomized trial evidence, that treating mild subclinical hypothyroidism in older adults does not reliably improve symptoms. It is not established what the single "right" TSH target is for every symptomatic adult with a normal-range but higher-than-personal-baseline TSH; this is an area of clinical judgment rather than a fixed rule.

Levothyroxine: the standard treatment

Levothyroxine (LT4) is the synthetic form of T4 and is the standard first-line treatment for hypothyroidism requiring hormone replacement. In most patients, the body converts a sufficient portion of T4 to active T3 peripherally, so T4 alone restores adequate hormone levels at the cellular level for the large majority of patients.

Dosing is individualized and titrated by TSH response rather than fixed at a single number for every patient. Older adults, and anyone with coronary artery disease, are typically started at a lower dose and titrated upward more slowly than a younger, otherwise healthy adult, because a too-rapid increase in thyroid hormone can strain the heart. TSH is generally rechecked roughly 6 to 8 weeks after any dose change, since that is roughly how long it takes for TSH to settle at its new steady state; checking sooner tends to produce a misleading result.

Absorption matters. Calcium carbonate, iron supplements, proton pump inhibitors, and soy products can all reduce levothyroxine absorption. Most guidance recommends taking levothyroxine on an empty stomach, well separated in time from other medications and supplements that interfere with absorption. A patient with an unexpectedly high TSH despite an adequate dose should be asked about the timing of calcium, iron, and antacid use before the dose is increased.

Brand versus generic. Regulatory bioequivalence standards allow a range of acceptable variation between approved levothyroxine products. Because even small shifts in absorbed dose can move TSH, it is reasonable clinical practice to stay on the same formulation once stable and to recheck TSH after any unplanned brand or manufacturer switch, rather than assuming all levothyroxine products behave identically in every patient.

Guideline bodies describe the goal of levothyroxine therapy as normalizing TSH and resolving symptoms attributable to thyroid hormone deficiency specifically, an important caveat, because not every symptom a hypothyroid patient has will necessarily resolve with hormone replacement if it has another cause.

Why do some patients still have symptoms on a "normal" TSH?

A meaningful minority of patients on an apparently adequate levothyroxine dose continue to report fatigue, brain fog, or other symptoms despite a TSH that falls within the standard reference range. This is a genuine and reasonably common clinical scenario, not a fringe complaint, though the exact proportion affected varies across studies and should not be treated as a precise, fixed statistic.

Persistent symptoms have several possible explanations that are worth working through in order, rather than jumping straight to combination hormone therapy:

• The TSH may be "normal" but higher than that individual's own pre-disease set-point. A TSH of 3.8 mIU/L can represent under-replacement in someone whose personal baseline was closer to 1.0-1.5 mIU/L.
• Coexisting, unrelated conditions are common and treatable in their own right: iron deficiency, vitamin B12 deficiency, obstructive sleep apnea, depression, and celiac disease (which co-occurs with autoimmune thyroid disease at a meaningfully higher rate than in the general population).
• Impaired peripheral conversion of T4 to T3 is biologically plausible in some patients and has been linked in research settings to variation in the DIO2 gene, though this remains an area of active investigation rather than routine clinical practice.

For patients whose T4 dose is optimized, whose TSH sits appropriately in range, and for whom other causes have genuinely been ruled out, a time-limited trial of combination T4/T3 therapy, either low-dose liothyronine (LT3) added to levothyroxine, or desiccated thyroid extract (DTE, a porcine-derived preparation containing both T4 and T3), is a recognized, guideline-acknowledged option after informed discussion, not a routine first step. Major guideline bodies describe the trial evidence for combination therapy as insufficient to recommend it broadly, while still allowing that an individualized trial can be appropriate for carefully selected patients with persistent symptoms.

A decision framework for persistent symptoms despite levothyroxine

Use this in order. Each step should change what happens next; skipping ahead to combination therapy without the earlier steps is the most common failure mode in this scenario.

The point of the sequence is that "normal TSH plus ongoing symptoms" has several competing explanations, and combination hormone therapy is the option with the least trial evidence behind it. It should be reached last, not first.

Hashimoto's thyroiditis: the autoimmune process behind most cases

Hashimoto's is not simply "a slow thyroid." It is a chronic autoimmune process that can move through phases: normal thyroid function, a transient hyperthyroid phase as damaged follicles leak stored hormone (sometimes called Hashitoxicosis), and eventually progressive hypothyroidism as functioning tissue is lost.

Anti-TPO antibody titers do not directly drive treatment decisions, and no currently available therapy reliably lowers antibody levels or halts the underlying autoimmune process. Selenium supplementation has been studied for modest reductions in anti-TPO titers in small trials, but evidence that it improves symptoms is weak, and supplementing without medical guidance is not advised given that excess selenium carries its own risks.

Gluten-free diets are widely discussed in patient communities, but evidence does not support routine gluten restriction in Hashimoto's patients who do not have confirmed celiac disease or diagnosed non-celiac gluten sensitivity. Because autoimmune thyroid disease and celiac disease co-occur more often than chance would predict, checking celiac antibodies is a reasonable step before recommending a significant dietary change, rather than adopting gluten avoidance on the assumption that it will help.

Hyperthyroidism and Graves' disease: the opposite pole, not a variant

Hypothyroidism and hyperthyroidism sit at opposite ends of the same feedback loop and share the same first screening test, TSH, but they are different conditions with different treatments. A suppressed TSH together with an elevated free T4 or free T3 indicates hyperthyroidism rather than hypothyroidism.

Graves' disease, an autoimmune condition in which antibodies stimulate the TSH receptor directly, is the most common cause of hyperthyroidism. Typical features include a diffuse goiter, bulging eyes (exophthalmos) in a substantial subset of patients, rapid heart rate, weight loss despite normal or increased appetite, heat intolerance, and tremor. Treatment options, antithyroid medication (methimazole, or propylthiouracil specifically in the first trimester of pregnancy), radioactive iodine ablation, and surgery, are all considered acceptable first-line choices by current guideline bodies, with the choice guided by patient preference, comorbidities, and access. This is a distinct diagnostic and treatment pathway from hypothyroidism and is covered here only to clarify that "thyroid disease" is not one condition with one direction.

Hypothyroidism in pregnancy

Uncontrolled hypothyroidism during pregnancy carries real risks, including miscarriage, preeclampsia, preterm birth, and impaired fetal neurodevelopment, because the fetus depends on maternal thyroid hormone before its own thyroid becomes functional partway through gestation.

Guideline bodies including the Endocrine Society generally recommend a TSH target below roughly 2.5 mIU/L in the first trimester for women already on levothyroxine, with dose increases often needed as soon as pregnancy is confirmed and TSH monitored at regular intervals through mid-pregnancy. The U.S. Preventive Services Task Force has previously found insufficient evidence to recommend universal thyroid screening for all asymptomatic pregnant women, while targeted screening of women with prior thyroid disease, type 1 diabetes, or a family history of autoimmune thyroid disease is standard practice. Any pregnant patient with known or suspected hypothyroidism should coordinate dose adjustments directly with their obstetric and endocrine clinicians rather than adjusting independently; this article does not provide individualized dosing guidance.

Long-term monitoring, and why over-replacement is not "safer than under"

Once stable on levothyroxine, most patients have TSH checked roughly every 6 to 12 months, with more frequent checks around life events that shift dose requirements: pregnancy, substantial weight change, aging past 65 (where TSH targets are often relaxed somewhat to reduce the risk of atrial fibrillation and bone loss from over-replacement), and starting or stopping medications that affect levothyroxine absorption or metabolism.

Over-replacement (a persistently suppressed TSH, well below the reference range) is not a harmless margin of error. It has been associated with increased risk of atrial fibrillation and accelerated bone loss, particularly in postmenopausal women, which is why "as long as I feel good" is not, on its own, an adequate substitute for lab monitoring.

There is emerging exploratory research examining thyroid hormone sensitivity measures (for example, a "thyroid feedback quartile index") and liver fibrosis risk in patients with treated primary hypothyroidism who also have metabolic dysfunction-associated steatotic liver disease and type 2 diabetes. A 2026 cross-sectional study reported an association between this index and fibrosis risk markers in this specific population (cross-sectional study, 2026). This is exploratory, cross-sectional evidence in a metabolically complex population, not a basis for changing thyroid dosing targets on its own; it is worth flagging to clinicians managing patients with hypothyroidism alongside fatty liver disease and diabetes as an area to watch, not an established monitoring requirement.

Iodine intake. Iodine deficiency remains the leading global cause of hypothyroidism, though it is uncommon in the fortified U.S. food supply. Adults generally should stay near standard recommended iodine intake levels and avoid high-dose iodine or kelp supplements without medical guidance, since excess iodine can paradoxically worsen thyroid function in susceptible individuals.

When to seek urgent care

Routine hypothyroidism symptoms and lab monitoring belong with a primary care clinician or endocrinologist on a scheduled basis. Seek urgent or emergency care instead for:

• Confusion, extreme lethargy, or unresponsiveness in a person with known hypothyroidism
• Very slow breathing, significant hypothermia, or collapse
• New chest pain, palpitations, or shortness of breath after a levothyroxine dose change, particularly in someone with heart disease
• Signs of a severe allergic reaction to a new thyroid medication

A note on the evidence in this article

Guideline-level recommendations described here (TSH targets, treatment thresholds for subclinical disease, pregnancy targets, combination-therapy caveats) reflect general positions attributed to bodies such as the American Thyroid Association, the Endocrine Society, and the U.S. Preventive Services Task Force. Exact numeric thresholds, trial sample sizes, and progression rates should be confirmed against current primary guideline documents before being used for an individual treatment decision, since guidelines are periodically revised and this article is not a substitute for that verification. Where a specific research citation is unverified against the primary literature, we have described the finding narratively and cautiously rather than attaching a numbered reference to it.

References

• Two Decades of Endocrine Silence: Severe Hyponatremia Presenting as Late-Onset Sheehan Syndrome (case report, 2026). https://pubmed.ncbi.nlm.nih.gov/42643646/
• Association between thyroid feedback quartile index and FIB-4-defined fibrosis risk in patients with metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus, and treated primary hypothyroidism: an exploratory cross-sectional study (2026). https://pubmed.ncbi.nlm.nih.gov/42638674/